CXCL13 Protein (AA 23-94)

Catalog No. ABIN2666638

This Recombinant CXCL13 protein is produced in Escherichia coli (E. coli).

Quick Overview for CXCL13 Protein (AA 23-94) (ABIN2666638)

Target: CXCL13 (Chemokine (C-X-C Motif) Ligand 13 (CXCL13))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (IHC)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 23-94

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract Baf3-hCXCR5 transfectants in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CXCL13 (Chemokine (C-X-C Motif) Ligand 13 (CXCL13))

Alternative Name: CXCL13

Background: CXCL13 was initially described as a chemokine highly expressed in the follicles of Peyer's patches, spleen, and lymph nodes and as a strong chomoattractant for B cells. CXCL13 is expressed by T follicular helper cells, dendritic cells, and stromal cells in B cell areas of secondary lymphoid tissue. CXCR5, the receptor for CXCL13, was initially cloned from Burkitt's lymphoma cells and named BLR1. CXCR5 is highly expressed in those cells and B cells. CXCL13, CCL19, and CCL21 are involved in the formation of tertiary lymphoid tissues in chronic antigen-induced arthritis. CXCL13 takes part in the allergic airway inflammatory process. In addition, high expression of CXCL13 has been linked to lupus, Helicobacter pylori-associated gastritis, multiple sclerosis, and rheumatoid arthritis. In summary, CXCL13 is highly expressed at the sites of new lymphoid tissue formation in a variety of chronic inflammatory conditions.

Molecular Weight: The 72 amino acid recombinant protein has a predicted molecular mass of approximately 8.6 kDa. The DTT-reduced and non-reduced protein migrate at approximately 12 kDa by SDS-PAGE. The N-terminal amino acid is Val.